Printer Friendly

MAGAININ PHARMACEUTICALS RECEIVES PATENT FOR SQUALAMINE

 PLYMOUTH MEETING, Pa., March 30 /PRNewswire/ -- Magainin Pharmaceuticals Inc. (NASDAQ: MAGN) today announced that the U.S. Patent Office has issued Patent No. 5,192,756 for the composition and use of squalamine as a broad spectrum antibiotic.
 Scientists believe that squalamine, an aminosterol antibiotic first isolated from tissues of the dogfish shark, represents a new class of antibiotic agent. It has shown activity against bacteria, fungi and protozoa. Magainin scientists believe squalamine, a member of the steroid chemical class, has the potential to be developed as an orally administered systemic anti-infective. The discovery of squalamine was reported in the February 1993 issue of Proceedings of the National Academy of Sciences.
 "The need for new anti-infectives becomes more apparent as bacterial pathogens become increasingly resistant to current antibiotic therapies. The discovery of squalamine strengthens our leadership in the discovery of new anti-infectives from the host defense systems of animals. We remain committed to that mission and to developing squalamine and other compounds in our pipeline into drugs to treat unmet human therapeutic needs," said Jay Moorin, president and chief executive officer of Magainin Pharmaceuticals Inc.
 The patent was issued to Dr. Michael Zasloff, currently executive vice president of Magainin Pharmaceuticals and president of the Magainin Research Institute, as well as his colleagues Karen Moore and Suzanne Wehrli. The company has an exclusive worldwide patent license agreement for squalamine.
 Magainin Pharmaceuticals Inc. is a biopharmaceutical company dedicated to the research, development and commercialization of anti- infectives and anti-cancer products based upon compounds isolated from the host defense systems of animals. Earlier this year the company launched Phase II clinical trials for MSI-78, its broad spectrum topical antibiotic.
 -0- 3/30/93
 /CONTACT: Jay Moorin of Magainin Pharmaceuticals, 215-941-4020, or Fern Lazar of Dewe Rogerson, 212-688-6840, for Magainin Pharmaceuticals/
 (MAGN)


CO: Magainin Pharmaceuticals Inc. ST: Pennsylvania IN: MTC SU:

TS-PS -- NY017 -- 0871 03/30/93 08:45 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 30, 1993
Words:316
Previous Article:SYSTEMIX DISCOVERY OF PLURIPOTENT STEM CELLS NAMED ONE TOP 10 MEDICAL ADVANCES OF 1992
Next Article:PHILAPRIDE ANNOUNCES DONALDSON AWARD WINNER; RONALD RUBIN TO ACCEPT
Topics:


Related Articles
MAGAININ PHARMACEUTICALS RECEIVES PATENT FOR WOUND HEALING DRUGS
MAGAININ PHARMACEUTICALS INC. ANNOUNCES MANUFACTURING PROCESS BREAKTHROUGH FOR ITS LEAD DRUG, MSI-78
SCIENTISTS ISOLATE NEW ANTIBIOTICS FROM SHARK
MAGAININ ANNOUNCES THE ISSUANCE OF THREE PATENTS
MAGAININ'S SQUALAMINE INHIBITS SOLID TUMOR GROWTH
Magainin Pharmaceuticals Raises $12 Million in Private Placement
Magainin Pharmaceuticals Announces Third Quarter Financial Results
Magainin Begins Phase I Human Clinical Testing of Squalamine for Cancer Also Presents Preclinical Data in Breast Cancer
Magainin Announces 1997 Financial Results

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters